Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2023 Earnings Call Transcript

Christal Mickle: Great. Thank you very much. We’re excited about our progress in the first half of 2023 and are looking ahead to continue our momentum. As we look forward to the second half and into 2024, we’re focused on the following 3 top priorities: First, to resubmit the arimoclomol NDA to the FDA and strengthened key functions and capabilities to support a successful launch of approved. Second, to complete the Phase II trial of idiopathic hypersomnia and prepare to advance KP1077 into a Phase III trial sometime next year. And third, to continue our work to expand our KP1077 program into narcolepsy. Corporate development also remains a priority as we actively engage in conversations to potentially acquire new pipeline assets that would be complementary to our portfolio, and that could benefit from the potential application of our prodrug technology.

We’re building something really special here at Zevra. We have a legacy of drug development success upon which we are expanding our capabilities by adding an innovative patient-first commercial team, which we believe has the potential to drive meaningful value for our shareholders. But not only that, we’re fully committed to our mission of bringing much needed therapies to people living with rare disease. Patients, caregivers, and all of those who are supporting the rare disease communities that we serve are at the forefront of everything that we do. I want to thank our shareholders for your continuing support of our efforts. Additionally, I want to give a special thanks to our employees for their energy, enthusiasm and relentless commitment to make Zevra’s success.

We’re excited about the prospects, opportunities and potential for success in front of us. Thank you for joining us today, and we look forward to speaking with you in the future.

Operator: This concludes today’s Zevra Therapeutics second quarter 2023 earnings call and webcast. You may disconnect your line at this time, and have a wonderful day.